Citations

Mayo Clinic

Clear

14 citation(s) found for "O'Gara, B P".

Guidelines Update on Indications for Transcatheter Aortic Valve Replacement
Nishimura, Rick A., Bonow, Robert O. , O’Gara, Patrick T.

JAMA Cardiology | August 2, 2017 | Volume: 2 | Issue: 9 | Pages: 1036

10.1001/jamacardio.2017.2546 | PMID 28768333 Get It

miR30a Inhibits LOX Expression and Anaplastic Thyroid Cancer Progression
Boufraqech, Myriem , Nilubol, Naris , Gara, Sudheer Kumar, Sadowski, Samira M. , Mehta, Amit, Davis, Sean , Dreiling, Jennifer L., Copland, John A. , Smallridge, Robert C., Quezado, Martha , Kebebew, Electron , Zhang, Lisa M. , He, Mei

Cancer Research | December 9, 2014 | Volume: 75 | Issue: 2 | Pages: 367-377

10.1158/0008-5472.can-14-2304 | PMID 25488748 Get It

Abstract Anaplastic thyroid cancer (ATC) is one of the most lethal human malignancies, but its genetic drivers remain little understood. In this study, we report losses in expression of the miRNA miR30a, which is downregulated in ATC compared with differentiated thyroid cancer and normal tissue. miR30a downregulation was associated with advanced differentiated thyroid cancer and higher mortality. Mechanistically, we found miR30a decreased cellular invasion and migration, epithelial–mesenchymal transition marker levels, lysyl oxidase (LOX) expression, and metastatic capacity. LOX was identified as a direct target of miR30a that was overexpressed in ATC and associated with advanced differentiated thyroid cancer and higher mortality rate. Consistent with its role in other cancers, we found that LOX inhibited cell proliferation, cellular invasion, and migration and metastasis in vitro and in vivo. Together, our findings establish a critical functional role for miR30a downregulation in mediating LOX upregulation and thyroid cancer progression, with implications for LOX targeting as a rational therapeutic strategy in ATC. Cancer Res; 75(2); 367–77. ©2014 AACR.
Aortic Diameter ≥5.5 cm Is Not a Good Predictor of Type A Aortic Dissection
Pape, Linda, Tsai, Thomas T., Oh, Jae K. , Evangelista, Arturo , Fattori, Rossella , Meinhardt, Gabriel, Trimarchi, Santi , Bossone, Eduardo , Cooper, Jeanna V., Froehlich, James B. , Isselbacher, Eric M. , O’Gara, Patrick T. , Suzuki, Toru , Nienaber, Christoph , Eagle, Kim A. , Bossone, Eduardo

Circulation | August 21, 2007 | Volume: 116 | Issue: 10 | Pages: 1120-1127

10.1161/circulationaha.107.702720 | PMID 17709637 Get It

Background— Studies of aortic aneurysm patients have shown that the risk of rupture increases with aortic size. However, few studies of acute aortic dissection patients and aortic size exist. We used data from our registry of acute aortic dissection patients to better understand the relationship between aortic diameter and type A dissection. Methods and Results— We examined 591 type A dissection patients enrolled in the International Registry of Acute Aortic Dissection between 1996 and 2005 (mean age, 60.8 years). Maximum aortic diameters averaged 5.3 cm; 349 (59%) patients had aortic diameters <5.5 cm and 229 (40%) patients had aortic diameters <5.0 cm. Independent predictors of dissection at smaller diameters (<5.5 cm) included a history of hypertension (odds ratio, 2.17; 95% confidence interval, 1.03 to 4.57; P =0.04), radiating pain (odds ratio, 2.08; 95% confidence interval, 1.08 to 4.0; P =0.03), and increasing age (odds ratio, 1.03; 95% confidence interval, 1.00 to 1.05; P =0.03). Marfan syndrome patients were more likely to dissect at larger diameters (odds ratio, 14.3; 95% confidence interval, 2.7 to 100; P =0.002). Mortality (27% of patients) was not related to aortic size. Conclusions— The majority of patients with acute type A acute aortic dissection present with aortic diameters <5.5 cm and thus do not fall within current guidelines for elective aneurysm surgery. Methods other than size measurement of the ascending aorta are needed to identify patients at risk for dissection.